Boehringer takes nintedanib to EMA; California governor vetoes biosimilars bill;

@FierceBiotech: Analysts offer giddy forecasts for booming cancer immunotherapy pipeline. More | Follow @FierceBiotech

@JohnCFierce: PhIII blunders that have helped define companies, for better or worse. The top Phase III R&D setbacks of 2013 | Follow @JohnCFierce

@DamianFierce: If Myriad was a big dog in a small park in its fight with Ambry and Gene by Gene, Quest is a dog colossus. | Follow @DamianFierce

> Boehringer Ingelheim has filed for EMA approval for nintedanib, a non-small cell lung cancer treatment. Article

> California Gov. Jerry Brown has vetoed a bill that would have allowed pharmacists to automatically replace biologics with biosimilars once the FDA declared the two interchangeable. Story

> Cel-Sci ($CVM) has signed a codevelopment and profit-sharing deal with CRO Ergomed, covering its cancer drug Multikine in cervical dysplasia patients with HIV and HPV. More

Medical Device News

@FierceMedDev: Natera expands prenatal test amid global push. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Who are this year's FMD Fierce 15 winners? Find out here | Follow @MarkHFierce

@MichaelGFierce: Critical Diagnostics launches point-of-care cardiac disease test. Item | Follow @MichaelGFierce

> J&J's med tech biz falters amid weak sales, M&A rumors. Story

> Senate debt, government funding compromise avoids addressing device tax repeal. Report

Pharma News

@FiercePharma: Biggest new news Monday: Irate Teva reps vow to strike against Israeli job cuts. Story | Follow @FiercePharma

@CarlyHFierce: Sanofi nabs OTC nod for Nasacort amid consumer healthcare push. ICYMI yesterday | Follow @CarlyHFierce

> J&J hikes earnings forecast on pharma's superhero sales flight. More

> Savient gives up the ghost; buyer aims to snap up Krystexxa. Article

Biotech Research News

@EmilyMFierce: Parkinson's may take two forms, one more toxic than the other. More | Follow @EmilyMFierce

> Vegetable-based compound protects against side effects of radiation therapy. Story

> Evotec gets $5.4M from Boehringer Ingelheim in cancer research pact. Report

> Compound halts neurodegeneration in mice. More

> Gene therapy plus stem cells quickens wound healing. Article

> Boston University, MRC Technology developing anti-inflammatory antibody. Item

Pharma Manufacturing News

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article | Follow @EricPFierce

> U.S. awards special status to fired Novartis workers. Report

> Israeli unions threaten strikes over Teva job cuts. Item

> FDA closes out inspection on Ranbaxy New Jersey plant. More

> SAFC adds biologics capabilities at 2 plants. News

> Roche expanding biologics production in 3 countries. Story

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.